- Home
- SGN vs KPRX Comparison
SGN vs KPRX Comparison
Compare SGN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- KPRX
- Stock Information
- Founded
- SGN 2019
- KPRX 1998
- Country
- SGN United States
- KPRX United States
- Employees
- SGN N/A
- KPRX N/A
- Industry
- SGN
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SGN
- KPRX Health Care
- Exchange
- SGN Nasdaq
- KPRX Nasdaq
- Market Cap
- SGN 7.8M
- KPRX 9.2M
- IPO Year
- SGN 2023
- KPRX N/A
- Fundamental
- Price
- SGN $1.19
- KPRX $1.87
- Analyst Decision
- SGN
- KPRX Strong Buy
- Analyst Count
- SGN 0
- KPRX 1
- Target Price
- SGN N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SGN 89.7K
- KPRX 51.4K
- Earning Date
- SGN 11-12-2025
- KPRX 11-07-2025
- Dividend Yield
- SGN N/A
- KPRX N/A
- EPS Growth
- SGN N/A
- KPRX N/A
- EPS
- SGN N/A
- KPRX N/A
- Revenue
- SGN $366,344.00
- KPRX N/A
- Revenue This Year
- SGN N/A
- KPRX N/A
- Revenue Next Year
- SGN N/A
- KPRX N/A
- P/E Ratio
- SGN N/A
- KPRX N/A
- Revenue Growth
- SGN N/A
- KPRX N/A
- 52 Week Low
- SGN $0.44
- KPRX $1.79
- 52 Week High
- SGN $8.60
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- SGN 35.75
- KPRX 27.45
- Support Level
- SGN $1.15
- KPRX $1.79
- Resistance Level
- SGN $1.61
- KPRX $2.39
- Average True Range (ATR)
- SGN 0.11
- KPRX 0.11
- MACD
- SGN -0.01
- KPRX -0.04
- Stochastic Oscillator
- SGN 9.64
- KPRX 8.24
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.